title: Recommended indications for the administration of polyclonal immunoglobulin preparations.
abstract: The following recommendations, which aim at standardising and rationalising the clinical indications for administering polyclonal immunoglobulins in Belgium, were drawn up by a working group of the Superior Health Council. To this end, the Superior Health Council organised an expert meeting devoted to"Guidelines for the use of immunoglobulins". The experts discussed the indications for immunoglobulin use, the'ideal'immunoglobulin preparation, its mechanisms of action, the practical issues involved in administering immunoglobulins and their potential side effects. The recommendations formulated by the experts were validated by the Superior Health Council working group with the purpose of harmonising immunoglobulin use in Belgium
authors.affiliation: Afdeling Hematologie, Universitaire Ziekenhuizen Leuven (KUL), Leuven, Belgium. michel.delforge@uzleuven.be
authors.forename: M
authors.initials: M
authors.lastname: Delforge
authors.forename: C M
authors.initials: CM
authors.lastname: Farber
authors.forename: P
authors.initials: P
authors.lastname: Spath
authors.forename: S
authors.initials: S
authors.lastname: Kaveri
authors.forename: T
authors.initials: T
authors.lastname: Witte
authors.forename: S A
authors.initials: SA
authors.lastname: Misbah
authors.forename: R
authors.initials: R
authors.lastname: Hübner
authors.forename: F
authors.initials: F
authors.lastname: Haerynck
authors.forename: D
authors.initials: D
authors.lastname: Latinne
authors.forename: L
authors.initials: L
authors.lastname: Muylle
authors.forename: M
authors.initials: M
authors.lastname: Toungouz
authors.forename: V
authors.initials: V
authors.lastname: Deneys
mesh_terms: D001530:Belgium; D019317:Evidence-Based Medicine; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors